Real-world outcomes after anifrolumab initiation in systemic lupus erythematosus: a pragmatic treat-to-target analysis. (PubMed, Clin Rheumatol) - Oct 6, 2026 - "After anifrolumab initiation, the proportion of evaluable patients meeting the pragmatic composite increased alongside reductions in disease activity and glucocorticoid dose. These exploratory findings suggest a potential role for anifrolumab within T2T strategies and warrant confirmation in larger controlled studies using validated treatment targets."
Journal • Real-world evidence • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Lupus • Pneumonia • Respiratory Diseases • Systemic Lupus Erythematosus
|
|
Benjamin Fernández Gutierrez; Cristina Lajas Petisco; Cristina Martinez Prada; Dalifer Freites Nuñez; Lydia Abasolo; Paloma Camarero Diaz; Sara Rodríguez Montes
|